SLU-PP-332,
does it really help with Improved human endurance and muscle function without exercise?
research showsSLU-PP-332 is rated ? because no human efficacy literature shows that it improves endurance or muscle function without exercise. Searches of PubMed and ClinicalTrials.gov found no human efficacy trial of SLU-PP-332. The original development article studied muscle cells and mice: twelve-week-old male mice received 50 mg/kg by intraperitoneal injection twice daily for about one week before treadmill testing and ran about 70% longer and 45% farther. A two-week mouse experiment also reported a grip-strength signal, and a separate study in obese mice found changes in fat mass and metabolism, but none can establish human benefit or safety. Online sale as an exercise-mimetic capsule or injection does not make it a clinical medicine and does not support self-administration of a research chemical.
ads claimOnline vendors describe SLU-PP-332 as an exercise mimetic that builds aerobic capacity and muscle without exercise and sell capsules, oral liquids, or injectable research products. The actual source record consists of cells and intraperitoneally dosed mice; no human dose, purity, absorption, efficacy, or safety evidence exists.
Useful facts when choosing a product
- SLU-PP-332 is not a peptide; it is a synthetic small-molecule research tool designed to activate ERR-alpha, beta, and gamma.
- The representative mouse experiment used 50 mg/kg by intraperitoneal injection and did not establish an oral or subcutaneous human regimen.
- Online research products are not approved medicines, and their labeled content, purity, contamination control, and sterility cannot be assumed.
- Human pharmacokinetics, maximum tolerated dose, short- or long-term toxicity, and reproductive, cardiovascular, and hepatic safety are not established, so no evidence supports self-use.
What the research actually shows
Billon 2023 tested whether SLU-PP-332 activates ERR-alpha, beta, and gamma and increases mitochondrial function and respiration in muscle cells. Male C57BL/6J mice received 50 mg/kg twice daily by intraperitoneal injection before treadmill exhaustion testing; treated mice ran about 70% longer and 45% farther than controls. The effect disappeared in mice with muscle-specific deletion of ERR-alpha, supporting mechanism dependence. Billon 2024 evaluated energy expenditure, fatty-acid oxidation, fat mass, and insulin sensitivity in diet-induced obese or ob/ob mice, but it was also nonhuman research. As of the verification search, PubMed and ClinicalTrials.gov contained no human dosing efficacy trial of SLU-PP-332.
Why this is classified as ?
ERR activation, oxidative muscle fibers, running performance, and metabolic changes have been reported in cells and mice, but no human efficacy trial has administered SLU-PP-332. The boundary between ? and D therefore clearly supports ?.
Counterpoint. The preclinical findings are useful as a starting point for future drug development. Until phase 1 safety, oral bioavailability, dose-response, and controlled efficacy trials exist, they cannot be interpreted as a human performance aid.
Rejudgment record. New verdict — Under the ? versus D rule, no human efficacy trial receives ?, while an available but null human trial receives D. Searches of PubMed and ClinicalTrials.gov found no SLU-PP-332 human efficacy trial, and the public primary evidence is limited to cells and intraperitoneally dosed mice
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved human endurance without exercise | ? | No human efficacy trial exists; the roughly 70% longer and 45% farther running result came from intraperitoneally dosed mice. |
| Improved human muscle function without exercise | ? | Grip strength and oxidative-fiber findings are limited to mice and cells, with no human data. |
| Improved human exercise performance with oral or injectable use | ? | Online formulation claims exist, but no oral or injectable human efficacy trial or established dose is available. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Billon C et al. 2023 | Preclinical cell-mechanism, genetic-deletion, and intraperitoneal mouse study | 0 | Academic support including NIH funding; compound developers were authors | ERR activation, muscle-cell respiration, oxidative muscle fibers, mouse running time and distance, and grip strength | Mice receiving 50 mg/kg twice daily by intraperitoneal injection ran about 70% longer and 45% farther, and the effect disappeared with muscle-specific ERR-alpha deletion. | Key preclinical evidence that cannot establish human efficacy |
| Billon C et al. 2024 | Preclinical study in diet-induced and genetic-obesity mouse models | 0 | Academic development research by the same compound-development group | Energy expenditure, fatty-acid oxidation, fat-mass accumulation, and insulin sensitivity | Obese mice showed exercise-like metabolic changes, but human endurance, muscle function, and safety were not evaluated. | Supporting preclinical evidence with complete human indirectness |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] SLU-PP-332 x improved human endurance and muscle function without exercise — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/slu-pp-332-human-endurance-muscle-function-without-exercise/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.